DGFT Amends Import Policy for Sulfadiazine API: Key Update for Pharma Sector

DGFT Amends Import Policy for Sulfadiazine API: Key Update for Pharma Sector

The Directorate General of Foreign Trade (DGFT) issued a notification amending the import policy for the Active Pharmaceutical Ingredient (API) Sulfadiazine, marking a crucial update for the domestic pharmaceutical industry.

Key Policy Change

• Policy Shift: The import policy for Sulfadiazine API has been shifted from the ‘Free’ category to the ‘Restricted’ category.
• Implication: This means that importers are now required to obtain a license or specific authorization from the DGFT before importing Sulfadiazine.

Sectoral Impact

• Support for Domestic Industry: This policy amendment is primarily intended to promote and protect the domestic manufacturing of Sulfadiazine API. By restricting imports, the government aims to reduce dependence on foreign suppliers and bolster local pharmaceutical production capabilities.
• Compliance Requirement: Pharmaceutical companies and traders who rely on imported Sulfadiazine must immediately comply with the new licensing requirements to ensure the continuity of their supply chain and manufacturing processes.
• Sulfadiazine Use: Sulfadiazine is an essential API often used in the manufacture of various antimicrobial drugs, making this policy change significant for the production of several key medicines.

Source :- Notification-No.-41_1